Uno studio di Pasritamig contro placebo nel carcinoma prostatico resistente alla castrazione metastatica in ritardo (MCRPC) (KLK2-comPAS)
Uno studio randomizzato di fase 3, in doppio cieco, controllato con placebo di Pasritamig (JNJ-78278343), un agente di reindirizzamento delle cellule T che mira a Kallikrein 2 umano, + migliore cure di supporto rispetto alle migliori cure di supporto per la cure metastatiche per la castrazione resistente alla castrazione.
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 with JNJ-87189401+BSC as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Study Contact
- Numero di telefono: 844-434-4210
- Email: Participate-In-This-Study1@its.jnj.com
Luoghi di studio
-
-
-
Heidelberg, Australia, 3084
- Reclutamento
- Warringal Private Hospital
-
Kurralta Park, Australia, 5037
- Reclutamento
- ICON Cancer Care
-
Melbourne, Australia, 3000
- Reclutamento
- Peter MacCallum Cancer Centre
-
Murdoch, Australia, 6150
- Reclutamento
- Fiona Stanley Hospital
-
Woolloongabba, Australia, 4102
- Reclutamento
- Princess Alexandra Hospital
-
-
-
-
-
Bruges, Belgio, 8000
- Reclutamento
- AZ Sint-Jan
-
Brussels, Belgio, 1200
- Reclutamento
- Cliniques Universitaires Saint Luc
-
Ghent, Belgio, 9000
- Reclutamento
- Ghent University Hospital
-
Ghent, Belgio, 9000
- Reclutamento
- AZ Maria Middelares
-
Kortrijk, Belgio, 8500
- Reclutamento
- Az Groeninge
-
La Louvière, Belgio, 7100
- Reclutamento
- Chu Helora Hospital La Louviere Site Jolimont
-
Liège, Belgio, 4000
- Reclutamento
- CHC MontLegia
-
Ottignies, Belgio, 1340
- Reclutamento
- Clinique Saint Pierre
-
Wilrijk, Belgio, 2610
- Reclutamento
- ZAS Augustinus
-
-
-
-
-
Florianópolis, Brasile, 88020 210
- Reclutamento
- Grupo ELORA Centro de Pesquisa e Ensino em Saude de Santa Catarina
-
Joinville, Brasile, 89201 260
- Reclutamento
- Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
-
Natal, Brasile, 59062 000
- Reclutamento
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre, Brasile, 90035-001
- Reclutamento
- Hospital Moinhos de Vento
-
São Paulo, Brasile, 01509 900
- Reclutamento
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Reclutamento
- Arthur J E Child Comprehensive Cancer Centre
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Reclutamento
- BC Cancer Vancouver
-
-
Ontario
-
Oshawa, Ontario, Canada, L1G2B9
- Reclutamento
- Lakeridge Health
-
Toronto, Ontario, Canada, M4N 3M5
- Reclutamento
- Sunnybrook Health Sciences Center
-
Toronto, Ontario, Canada, M5G 2C1
- Reclutamento
- Princess Margaret Hospital
-
-
Quebec
-
Québec, Quebec, Canada, G1J 1Z4
- Reclutamento
- CHU de Quebec Universite Laval
-
-
-
-
-
Beijing, Cina, 100034
- Reclutamento
- Peking University First Hospital
-
Changchun, Cina, 130021
- Reclutamento
- The First Bethune Hospital of Jilin University
-
Chengdu, Cina, 610041
- Reclutamento
- West China Hospital of Sichuan University
-
Chengdu, Cina, 500643
- Reclutamento
- The Third People's Hospital of Chengdu
-
Chongqing, Cina, 400030
- Reclutamento
- Chongqing University Cancer Hospital
-
Guangzhou, Cina, 510060
- Reclutamento
- Sun Yat Sen University Cancer Center
-
Nanjing, Cina, 210008
- Reclutamento
- Nanjing Drum Tower Hospital
-
Nanning, Cina, 530021
- Reclutamento
- The First Affiliated Hospital of Guangxi Medical University
-
Nantong, Cina, 226300
- Reclutamento
- Nantong Tumor Hospital
-
Ningbo, Cina, 315010
- Reclutamento
- The First Affiliated Hospital of Ningbo University
-
Shanghai, Cina, 200032
- Reclutamento
- Fudan University Shanghai Cancer Center
-
Tianjin, Cina, 300211
- Reclutamento
- The Second Hospital Of Tianjin Medical University
-
Wenzhou, Cina, 325000
- Reclutamento
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Cina, 430071
- Reclutamento
- Zhongnan Hospital Wu Han University
-
Xi'an, Cina, 710061
- Reclutamento
- The First Affiliated Hospital of Xian Jiaotong University
-
-
-
-
-
Daejeon, Corea del Sud, 35015
- Reclutamento
- Chungnam National University Hospital
-
Goyang-si, Corea del Sud, 10408
- Reclutamento
- National Cancer Center
-
Hwasungun, Corea del Sud, 58128
- Reclutamento
- Chonnam National University Hwasun Hospital
-
Seoul, Corea del Sud, 05505
- Reclutamento
- Asan Medical Center
-
Seoul, Corea del Sud, 06351
- Reclutamento
- Samsung Medical Center
-
Seoul, Corea del Sud, 03722
- Reclutamento
- Severance Hospital Yonsei University Health System
-
Seoul, Corea del Sud, 06591
- Reclutamento
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Bordeaux, Francia, 33000
- Reclutamento
- Institut Bergonie
-
Brest, Francia, 29200
- Reclutamento
- CHRU Brest - Hopital Morvan
-
Dijon, Francia, 21000
- Reclutamento
- Centre Georges Francois Leclerc
-
Lille, Francia, 59000
- Reclutamento
- Centre Oscar Lambret
-
Lyon, Francia, 69008
- Reclutamento
- Centre Leon Berard
-
Paris, Francia, 75014
- Reclutamento
- Hopital Saint Joseph
-
Pierre-Bénite, Francia, 69495
- Reclutamento
- CHU Lyon Sud
-
Saint-Herblain, Francia, 44805
- Reclutamento
- I.C.O. Rene Gauducheau
-
Strasbourg, Francia, 672098
- Reclutamento
- Hopitaux universitaires de Strasbourg
-
Vandœuvre-lès-Nancy, Francia, 54519
- Reclutamento
- Institut de Cancerologie de Lorraine
-
Villejuif, Francia, 94800
- Reclutamento
- Gustave Roussy
-
-
-
-
-
Braunschweig, Germania, 38126 DE
- Reclutamento
- Staedtisches Klinikum Braunschweig
-
Duisburg, Germania, 47169
- Reclutamento
- Urologicum Duisburg
-
Düsseldorf, Germania, 40225
- Reclutamento
- Universitaetsklinikum Duesseldorf
-
Essen, Germania, 45147
- Reclutamento
- Universitaetsklinikum Essen
-
Frankfurt am Main, Germania, 60488
- Reclutamento
- Krankenhaus NorthWest
-
Hamburg, Germania, 20246
- Reclutamento
- Martini-Klinik am UKE GmbH
-
Heidelberg, Germania, 69120
- Reclutamento
- Universitaetsklinikum Heidelberg Nationales Centrum fuer Tumorerkrankungen
-
München, Germania, 81675
- Reclutamento
- Klinikum rechts der Isar der TU Muenchen
-
Münster, Germania, 48149
- Reclutamento
- Universitaetsklinikum Muenster
-
Nuremberg, Germania, 90419
- Reclutamento
- Klinikum Nuernberg Nord
-
Nürtingen, Germania, 72622
- Reclutamento
- Studienpraxis Urologie Nurtingen
-
-
-
-
-
Bunkyō City, Giappone, 113 8519
- Reclutamento
- Institute of Science Tokyo Hospital
-
Fukuoka, Giappone, 812 8582
- Reclutamento
- Kyushu University Hospital
-
Gifu, Giappone, 501-1194
- Reclutamento
- Gifu University Hospital
-
Hidaka, Giappone, 350 1298
- Reclutamento
- Saitama Medical University International Medical Center
-
Kanazawa, Giappone, 920 8641
- Reclutamento
- Kanazawa University Hospital
-
Kashiwa, Giappone, 277 8577
- Reclutamento
- National Cancer Center Hospital East
-
Kobe, Giappone, 650 0017
- Reclutamento
- Kobe University Hospital
-
Matsuyama, Giappone, 791-0280
- Reclutamento
- National Hospital Organization Shikoku Cancer Center
-
Meguro Ku, Giappone, 152 8902
- Reclutamento
- National Hospital Organization Tokyo Medical Center
-
Sakura, Giappone, 285-8741
- Reclutamento
- Toho University Sakura Medical Center
-
Sapporo, Giappone, 060 8648
- Reclutamento
- Hokkaido University Hospital
-
Yokohama, Giappone, 232 0024
- Reclutamento
- Yokohama City University Medical Center
-
Yokohama, Giappone, 236 0004
- Reclutamento
- Yokohama City University Hospital
-
Yokosuka, Giappone, 238 8558
- Reclutamento
- Yokosuka Kyosai Hospital
-
-
-
-
-
Foggia, Italia, 71122
- Reclutamento
- Ospedali Riuniti Foggia
-
Milan, Italia, 20133
- Reclutamento
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Naples, Italia, 80131
- Reclutamento
- Azienda Ospedaliera Universitaria Federico II
-
Padova, Italia, 35128
- Reclutamento
- IOV IRCCS Padova
-
Palermo, Italia, 90127
- Reclutamento
- Azienda Di Rilievo Nazionale E Di Alta Specializzazione
-
Roma, Italia, 00168
- Reclutamento
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano, Italia, 20089
- Reclutamento
- Istituto Clinico Humanitas
-
Torino, Italia, 10126
- Reclutamento
- A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
-
-
-
-
-
Delft, Olanda, 2625 AD
- Reclutamento
- Reinier de Graaf Gasthuis
-
Groningen, Olanda, 9728NT
- Completato
- Martini Ziekenhuis
-
Hilversum, Olanda, 1212 VG
- Reclutamento
- Tergooi
-
Hoofddorp, Olanda, 2134 TM
- Reclutamento
- Spaarne Gasthuis
-
Maastricht, Olanda, 6229 HX
- Reclutamento
- Maastricht UMC
-
Nijmegen, Olanda, 6532 SZ
- Reclutamento
- Canisius-Wilhelmina ZH
-
Rotterdam, Olanda, 3015 GD
- Reclutamento
- Erasmus MC
-
Zwolle, Olanda, 8025 AB
- Reclutamento
- Isala Kliniek
-
-
-
-
-
Bialystok, Polonia, 15 276
- Reclutamento
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
Bydgoszcz, Polonia, 85 048
- Reclutamento
- IN VIVO Sp. z o.o
-
Koszalin, Polonia, 75-581
- Reclutamento
- Szpital Wojewodzki im Mikolaja Kopernika w Koszalinie
-
Warsaw, Polonia, 02 781
- Reclutamento
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Warsaw, Polonia, 04 073
- Reclutamento
- Szpital Grochowski Im Dr Med Rafala Masztaka Sp Z O O
-
-
-
-
-
Rio Piedras, Porto Rico, 00935
- Reclutamento
- Pan American Center for Oncology Trials LLC
-
San Juan, Porto Rico, 00917
- Reclutamento
- Puerto Rico Medical Research Center
-
-
-
-
-
Birmingham, Regno Unito, B15 2TH
- Reclutamento
- University Hospitals Birmingham NHS Foundation Trust
-
London, Regno Unito, WC1E 6BT
- Reclutamento
- University College London Hospitals
-
Manchester, Regno Unito, M20 4BX
- Reclutamento
- The Christie NHS Foundation Trust Christie Hospital
-
Sutton, Regno Unito, SM2 5PT
- Reclutamento
- Royal Marsden Hospital (Sutton)
-
-
-
-
-
Barcelona, Spagna, 08035
- Reclutamento
- Hosp Univ Vall D Hebron
-
Jerez de la Frontera, Spagna, 11407
- Completato
- Hosp. de Jerez de La Frontera
-
Madrid, Spagna, 28034
- Reclutamento
- Hosp. Univ. Ramon Y Cajal
-
Madrid, Spagna, 28041
- Reclutamento
- Hosp. Univ. 12 de Octubre
-
Málaga, Spagna, 29010
- Reclutamento
- Hosp Virgen de La Victoria
-
-
-
-
California
-
La Jolla, California, Stati Uniti, 92093
- Reclutamento
- University of California at San Diego
-
Los Angeles, California, Stati Uniti, 90048
- Reclutamento
- Cedars Sinai Medical Center
-
Los Angeles, California, Stati Uniti, 90095
- Reclutamento
- Ronald Reagan UCLA Medical Center
-
San Francisco, California, Stati Uniti, 94121
- Reclutamento
- San Francisco VA Medical Center
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Reclutamento
- University of Colorado Cancer Center
-
Aurora, Colorado, Stati Uniti, 80012
- Reclutamento
- Rocky Mountain Cancer Centers
-
Lakewood, Colorado, Stati Uniti, 80228
- Reclutamento
- Colorado Clinical Research
-
-
Connecticut
-
Hartford, Connecticut, Stati Uniti, 06102
- Reclutamento
- Hartford Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Stati Uniti, 20016
- Reclutamento
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
-
-
Florida
-
Bay Pines, Florida, Stati Uniti, 33744
- Reclutamento
- Bay Pines VA Healthcare System
-
Fort Myers, Florida, Stati Uniti, 33901
- Reclutamento
- Florida Cancer Specialists & Research Institute
-
Tampa, Florida, Stati Uniti, 33612
- Reclutamento
- Moffitt Cancer Center
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- Reclutamento
- University of Iowa Hospital and Clinics
-
Waukee, Iowa, Stati Uniti, 50263
- Reclutamento
- Mission Cancer Blood
-
-
Louisiana
-
Metairie, Louisiana, Stati Uniti, 70006
- Reclutamento
- East Jefferson General Hospital
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Reclutamento
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02115
- Reclutamento
- Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Reclutamento
- University of Michigan Health System
-
Detroit, Michigan, Stati Uniti, 48202
- Reclutamento
- Henry Ford Cancer Detroit
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455
- Reclutamento
- University Of Minnesota Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68130
- Completato
- XCancer Omaha / Urology Cancer Center
-
-
New York
-
Brooklyn, New York, Stati Uniti, 11220
- Reclutamento
- NYU Langone Hospitals
-
Mineola, New York, Stati Uniti, 11501
- Reclutamento
- NYU Langone Hospital Long Island
-
New York, New York, Stati Uniti, 10032
- Reclutamento
- Columbia University Medical Center
-
New York, New York, Stati Uniti, 10016
- Reclutamento
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28204
- Reclutamento
- Levine Cancer Institute
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Reclutamento
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45219
- Reclutamento
- University of Cincinnati
-
Cleveland, Ohio, Stati Uniti, 44106
- Reclutamento
- University Hospital of Cleveland
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97239
- Reclutamento
- VA Portland Health Care System
-
Portland, Oregon, Stati Uniti, 97227
- Completato
- Compass Oncology
-
Portland, Oregon, Stati Uniti, 97239
- Reclutamento
- Oregon Health And Science University
-
Springfield, Oregon, Stati Uniti, 97477
- Reclutamento
- Oregon Urology Institute
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Stati Uniti, 19004
- Reclutamento
- MidLantic Urology
-
Lancaster, Pennsylvania, Stati Uniti, 17601
- Reclutamento
- Keystone Urology Specialists
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Reclutamento
- Penn Medicine Abramson Cancer Center
-
Pittsburgh, Pennsylvania, Stati Uniti, 15232
- Reclutamento
- UPMC Cancer Centers
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29401
- Reclutamento
- Ralph H Johnson Veterans Hospital
-
Greer, South Carolina, Stati Uniti, 29650
- Reclutamento
- Gibbs Cancer Center and Research Institute Pelham
-
Myrtle Beach, South Carolina, Stati Uniti, 29572
- Reclutamento
- Carolina Urologic Research Center
-
Spartanburg, South Carolina, Stati Uniti, 29303
- Reclutamento
- Gibbs Cancer Center
-
-
Tennessee
-
Chattanooga, Tennessee, Stati Uniti, 37404
- Reclutamento
- Tennessee Oncology - Chattanooga
-
Nashville, Tennessee, Stati Uniti, 37203
- Reclutamento
- Tennessee Oncology Nashville
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75390
- Reclutamento
- UT Southwestern Medical Center
-
Dallas, Texas, Stati Uniti, 75231
- Completato
- Urology Clinics of North Texas
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- MD Anderson Cancer Center
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Michael E DeBakey VA Medical Center
-
Wichita Falls, Texas, Stati Uniti, 76310
- Reclutamento
- Texas Oncology West Texas
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84106
- Reclutamento
- Utah Cancer Specialists
-
-
Virginia
-
Fairfax, Virginia, Stati Uniti, 22031
- Reclutamento
- Virginia Cancer Specialists
-
Norfolk, Virginia, Stati Uniti, 23502
- Reclutamento
- Virginia Oncology Associates
-
Roanoke, Virginia, Stati Uniti, 24014
- Reclutamento
- Blue Ridge Cancer Care
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98195
- Reclutamento
- University of Washington
-
Seattle, Washington, Stati Uniti, 98109
- Reclutamento
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, Stati Uniti, 98108
- Reclutamento
- VA Puget Sound Healthcare System
-
-
-
-
-
Kaohsiung City, Taiwan, 833
- Reclutamento
- Chang Gung Memorial Hospital
-
Taichung, Taiwan, 40705
- Reclutamento
- Taichung Veterans General Hospital
-
Taichung, Taiwan, 435
- Reclutamento
- Tungs' Taichung MetroHarbor Hospital
-
Taipei, Taiwan, 100
- Reclutamento
- National Taiwan University Hospital
-
Taipei, Taiwan, 112
- Reclutamento
- Taipei Veterans General Hospital
-
Taoyuan, Taiwan, 333
- Reclutamento
- Linkou Chang Gung Memorial Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria
- Histologically confirmed adenocarcinoma of the prostate
- Metastatic castration-resistant prostate cancer (mCRPC): Disease that is metastatic either to bone, any lymph node, or both without clear evidence of other metastatic sites at the time of screening by conventional imaging with computed tomography (CT) or magnetic resonance imaging (MRI) (chest, abdomen, and pelvis) and 99m^Tc bone scan. Visceral disease is not allowed
- PSA greater than or equal to (≥) 2 nanogram per milliliter (ng/mL) at screening
- In the opinion of the investigator, the next best treatment option is a clinical trial
- Participants are required to have had all life-prolonging therapies for which they are clinically eligible in the opinion of the investigator and to which they have access. Prior therapies could have been given in any disease setting (not limited to mCRPC). In particular, prior treatment specifications include receipt of the following:
Androgen-receptor pathway inhibitor (ARPI): Must have progressed on at least 1 ARPI and unlikely to benefit from retreatment with another ARPI
Taxanes: Required to have received at least 2 previous taxane-based regimens. If a participant has received only 1 taxane regimen, the participant is eligible if:
- Cabazitaxel is not available
- The participant's physician deems the participant unsuitable to receive a second taxane regimen due to toxicity risk or prior intolerance Note: a taxane-based regimen consists of at least 2 cycles of a taxane (either as a single agent or in combination with other therapies) administered within the same 2-month period
Radioligand therapy: Required to have been previously treated with at least 1 dose of Prostate-specific membrane antigen (PSMA)-targeted lutetium radioligand therapy (eg, lutetium Lu-177 vipivotide tetraxetan), unless one of the following applies:
- PSMA-targeted lutetium radioligand therapy is unavailable, not accessible, or not clinically indicated.
- The participant's physician deems the participant unsuitable to receive PSMA-targeted lutetium radioligand therapy.
Polyadenosine diphosphate-ribose polymerase inhibitors (PARPi): Required to have been previously treated with PARPi, if the participant has a known germline or somatic BRCA mutation and treatment is available
- Prior orchiectomy or medical castration (receiving ongoing ADT with a GnRH analog [agonist or antagonist]) prior to the first dose of study treatment and must continue this therapy throughout the treatment phase
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Participants are eligible if they have the following values:
A) eGFR ≥ 40 milliliters per minute (mL/min) B) Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) less than or equal to (≤) 3 times the Upper Limit of Normal (ULN) C) Total bilirubin <1.5 times ULN D) Absolute neutrophil count (ANC) ≥ 1.0x10^9/per liter (L) E) Hemoglobin ≥ 8.0 grams per deciliter (g/dL) F) Platelet count ≥ 75x10^9/L
Exclusion Criteria
- Venous thromboembolic events within 1 month prior to the first dose of study treatment; uncomplicated (Grade ≤ 2) deep vein thrombosis is not exclusionary
- Active autoimmune disease within the past 12 months that requires systemic immunosuppressive medications (eg, chronic corticosteroid, methotrexate, or tacrolimus)
- Participants with Grade 1 or higher fever (≥38ºC) or active infection requiring systemic treatment within 7 days prior to randomization are ineligible. Participants must be afebrile (<38ºC) at the time of study treatment dosing unless approved by medical monitor
- Clinically significant pulmonary compromise, particularly a requirement for supplemental oxygen use (>2 liters per minute (L/min) by nasal cannula) to maintain adequate oxygenation
- Prior or concurrent second malignancy (other than the disease under study) for which natural history or treatment could likely interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Any of the following within 6 months prior to first dose of study treatment:
A) Myocardial infarction B) Severe or unstable angina C) Clinically significant ventricular arrhythmias D) Congestive heart failure (New York Heart Association class II to IV) E) Transient ischemic attack F) Cerebrovascular accident
- Prior treatment with any CD3-directed therapy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Part 1: Pasritamig+Best Supportive Care (BSC)
Participants in Part 1 will receive 2 step-up doses of pasritamig intravenously (IV) followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
Pasritamig will be administrated through IV infusion.
Altri nomi:
BSC will be administered at the discretion of the treating physician. |
|
Comparatore placebo: Part 1: Placebo+BSC
Participants in Part 1 will receive 2 step-up doses of placebo IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
BSC will be administered at the discretion of the treating physician. Placebo will be administrated through IV infusion. |
|
Sperimentale: Part 2: Pasritamig+BSC
Participants in Part 2 will receive 2 step-up doses of pasritamig IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
Pasritamig will be administrated through IV infusion.
Altri nomi:
BSC will be administered at the discretion of the treating physician. |
|
Sperimentale: Part 2: Pasritamig+JNJ-87189401+BSC
Participants in Part 2 will receive 2 step-up doses of pasritamig IV followed by the target dose. JNJ-87189401 will be administered with the first target dose of pasritamig. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
Pasritamig will be administrated through IV infusion.
Altri nomi:
BSC will be administered at the discretion of the treating physician. JNJ-87189401 will be administered. |
|
Comparatore placebo: Part 2: Placebo +BSC
Participants in Part 2 will receive 2 step-up doses of placebo IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
BSC will be administered at the discretion of the treating physician. Placebo will be administrated through IV infusion. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS)
Lasso di tempo: Up to 2 years and 8 months
|
OS is defined as the time from randomization to date of death due to any cause. |
Up to 2 years and 8 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Radiographic Progression-free Survival (rPFS)
Lasso di tempo: Up to 2 years and 8 months
|
rPFS assessed by investigator defined as the time from the date of randomization until the date of radiographic disease progression (based on response evaluation criteria in solid tumors [RECIST] version (v) 1.1 and prostate cancer working group 3 [PCWG3] criteria) or death, whichever comes first. |
Up to 2 years and 8 months
|
|
Time to Symptomatic Progression
Lasso di tempo: Up to 2 years and 8 months
|
Time to symptomatic progression is defined as time from the date of randomization to the date of any of the following (whichever occurs first): (a) the use of external beam radiation therapy to relieve cancer-related symptoms; (b) the need for tumor-related orthopedic surgical intervention; (c) other cancer-related procedures; (d) cancer-related morbid events; (e) initiation of a new systemic anti-cancer therapy because of cancer symptoms. |
Up to 2 years and 8 months
|
|
Time to Skeletal-Related Event
Lasso di tempo: Up to 2 years and 8 months
|
Time to skeletal-related event is defined as the time from the date of randomization to the date of first occurrence of any of the following (whichever occurs first): (a) the use of external beam radiation for skeletal or pelvic symptoms; b) the need for tumor-related orthopedic surgical intervention; (c) the occurrence of new bone fractures (cancer-related); (d) the occurrence of tumor-related spinal cord compression. |
Up to 2 years and 8 months
|
|
Progression-Free Survival (PFS)
Lasso di tempo: Up to 2 years and 8 months
|
PFS is defined as the date of randomization to the date of first evidence of radiographic progression, clinical progression, or death from any cause, whichever occurs first. |
Up to 2 years and 8 months
|
|
Time to Prostate Specific Antigen (PSA) Progression
Lasso di tempo: Up to 2 years and 8 months
|
Time to PSA progression, defined as the time from randomization to the first date of documented PSA progression per PCWG3 criteria. PSA progression is defined as: after a decline from baseline, PSA increases >= 25 percentage (%) and >= 2 nanograms per milliliter (ng/mL) above the nadir, confirmed by a second value >= 3 weeks later (that is, a confirmed rising trend), or If there is no decline from baseline, PSA increases >= 25 % and >= 2 ng/mL from baseline after 12 weeks. |
Up to 2 years and 8 months
|
|
Time to Pain Progression (TTPP) as Assessed by the Brief Pain Inventory-Short Form (BPI-SF) Item 3 Worst Pain in 24 Hours
Lasso di tempo: Up to 2 years and 8 months
|
TTPP is defined as the time from the date of randomization to the date of the first observation of pain progression. Pain progression is defined as an increase of at least 2 points from baseline in the BPI-SF worst pain intensity (item 3) observed at 2 consecutive evaluations >= 3 weeks apart. BPI-SF is an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score range from 0 to 10 with 0 representing "no pain" and 10 representing" pain as bad as you can imagine". |
Up to 2 years and 8 months
|
|
Time to Deterioration in Fatigue as Assessed by the European Organisation For Research And Treatment of Cancer Quality of Life Questionnaire-Core-30 (EORTC QLQ-C30) Fatigue Scale Score
Lasso di tempo: Up to 2 years and 8 months
|
Time to deterioration is defined as the time from randomization to the date of the first observation of deterioration in Fatigue. Deterioration in Fatigue is defined as an increase of 10 points on the EORTC QLQ-C30 FA scale observed at 2 consecutive evaluations >= 3 weeks apart. The EORTC QLQ-C30 is a widely used tool for assessing the quality of life of cancer patients in clinical trials. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent". Each subscale of the EORTC QLQ-C30 is scored on a range from 0 to 100. Higher scores indicate worse symptoms or problems. |
Up to 2 years and 8 months
|
|
Number of Participants with Adverse Events (AEs)
Lasso di tempo: Up to 2 years and 8 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 2 years and 8 months
|
|
Number of Participants with Abnormalities in Clinical Laboratory Assessments
Lasso di tempo: Up to 2 years and 8 months
|
Participants with abnormalities in clinical laboratory parameters (hematology, clinical chemistry etc.) will be assessed. |
Up to 2 years and 8 months
|
Collaboratori e investigatori
Investigatori
- Direttore dello studio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 78278343PCR3001
- 2025-520927-26-00 (Identificatore di registro: EUCT number)
- 2025 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .